Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy

BACKGROUND/AIMS: Chimeric antigen receptor (CAR) T cells for refractory or relapsed (r/r) B-cell acute lymphoblastic leukemia (ALL) patients have shown promising clinical effectiveness. However, the factors impacting the clinical response of CAR-T therapy have not been fully elucidated. We here aime...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Jingxian, Liu, Sining, Cui, Wei, Dai, Haiping, Cui, Qingya, Yin, Jia, Li, Zheng, Kang, Liqing, Qiu, Huiying, Han, Yue, Miao, Miao, Chen, Suning, Xue, Shengli, Wang, Ying, Jin, Zhengming, Zhu, Xiaming, Yu, Lei, Wu, Depei, Tang, Xiaowen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970344/
https://www.ncbi.nlm.nih.gov/pubmed/35371098
http://dx.doi.org/10.3389/fimmu.2022.858590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970344/
https://www.ncbi.nlm.nih.gov/pubmed/35371098
http://dx.doi.org/10.3389/fimmu.2022.858590

Ejemplares similares